title: Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine.
abstract: METHODS
  We present a case of a seventy-eight year-old man who developed vocal cord paralysis without any sign of peripheral neuropathy during the treatment of Mantle Cell Lymphoma. He first presented in 2008 with a few bilateral small inguinal lymph nodes. Inguinal lymph node biopsy demonstrated Mantle Cell Lymphoma. Flow cytometry studies of peripheral blood and bone marrow cells were compatible with Mantle Cell Lymphoma. R-CHOP chemotherapy triweekly (Rituximab; Cyclophosphamide; Adriamycin; Vincristine; and Methylprednisolone) was planned. At the end of the second cycle, the patient complained of hoarseness without any symptoms of dysphagia or odynophagia. Direct flexible laryngoscopy showed bilateral vocal cord paralysis. Vincristine was discontinued and the patient's voice gradually resolved in about 4 months.
  
  
  CONCLUSIONS
  Vincristine may cause peripheral, autonomic and cranial neuropathies. However cranial nerve involvement is quite uncommon.
authors: Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Fatih 34098, Turkey.
authors: Serkan Feyyaz
authors: SF
authors: Yalin
authors: Sinan
authors: S
authors: Trabulus
authors: Ayse Serap
authors: AS
authors: Yalin
authors: Gulsah Yenidunya
authors: GY
authors: Yalin
authors: Seniz
authors: S
authors: Ongoren
authors: Mehmet Riza
authors: MR
authors: Altiparmak
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005434:Flow Cytometry; D006801:Humans; D007828:Laryngoscopy / Q000379:methods; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014826:Vocal Cord Paralysis / Q000139:chemically induced*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone